Drug Trial Radar · NCT05436639
SPI-62 as a Treatment for Hypercortisolism Related to a Benign Adrenal Tumor
Last checked: Nov 19, 2026Latest source record: Feb 13, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
30
Actual
Start
Jul 1, 2023
Primary completion
Dec 1, 2024
Study completion Feb 18, 2025
Sponsor
- Lead sponsor
- Sparrow PharmaceuticalsIndustry
- Sponsor type
- Industry
- First posted
- Jun 29, 2022
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is study with SPI-62 to evaluate the efficacy, safety, and pharmacological effect of SPI-62 in subjects with hypercortisolism related to a benign adrenal tumor. Each subject will receive 2mg of SPI-62 daily.
Conditions
- Autonomous Cortisol Secretion (ACS)
- ACTH-Independent Cushing Syndrome
- ACTH-Independent Adrenal Cushing Syndrome, Somatic
Interventions
SPI-62 doseDrug
SPI-62 is an 11β hydroxysteroid dehydrogenase type 1 (HSD-1) inhibitor, supplied as oral tablets for dose 2 of drug (2mg).
Primary outcomes
What the sponsor says the trial is designed to measure.
- Change in HbA1c at Week 6Time frame: Baseline to week 6
- Change in HbA1c at week 12Time frame: Baseline to week 12
Locations
5 sites in 3 countries. Site status is shown where the registry gives one.
Mayo Clinic Cancer Center (MCCC) - Rochester
Rochester, Minnesota
Ohio State McCampbell Outpatient Care
Columbus, Ohio
C.M.D.T.A. Neomed
Brasov, Romania
Institutul National de Endocrinologie
Bucharest, Romania
King's College Hospital
London, United Kingdom
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.